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To adopt, to adapt, or to contextualise? 
The big question in clinical practice guideline 
development
Janine Margarita Dizon1,2*, Shingai Machingaidze3,4 and Karen Grimmer5
Abstract 
Aim: Developing new clinical practice guidelines (CPGs) can be time-consuming and expensive. A more efficient 
approach could be to adopt, adapt or contextualise recommendations from existing good quality CPGs so that the 
resultant guidance is tailored to the local context.
Results: The first steps are to search for international CPGs that have a similar purpose, end-users and patients to 
your situation. The second step is to critically appraise the methodological quality of the CPGs to ensure that your 
guidance is based on credible evidence. Then the decisions begin. Can you simply ‘adopt’ this (parent) clinical 
practice guidelines, and implement the recommendations in their entirety, without any changes, in your setting? If so, 
then no further work is required. However this situation is rare. What is more likely, is that even if recommendations 
from the parent clinical practice guidelines can be adopted, how they are implemented needs to address local issues. 
Thus you may need to ‘contextualise’ the guidance, by addressing implementation issues such as local workforce, 
training, health systems, equipment and/or access to services. Generally this means that additional information is 
required (Practice/Context Points) to support effective implementation of the clinical practice guidelines recommen-
dations. In some cases, you may need to ‘adapt’ the guidance, where you will make changes to the recommenda-
tions so that care is relevant to your local environments. This may involve additional work to search for local research, 
or obtain local consensus, regarding how best to adapt recommendations. For example, adaptation might reflect 
substituting one drug for another (drugs have similar effects, but the alternative drug to the recommended one may 
be cheaper, more easily obtained or more culturally acceptable). There is lack of standardisation of clinical practice 
guidelines terminology, leading clinical practice guideline activities often being poorly conceptualised or reported. 
We provide an approach that would help improve efficiency and standardisation of clinical practice guidelines 
activities.
Keywords: Clinical practice guidelines, Guideline development, Guideline adoption, Guideline adaptation, Guideline 
contextualisation
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The volume of literature available to support the construc-
tion of new (de novo) evidence-based clinical practice 
guidelines (CPGs) was recently highlighted by Schüne-
mann et  al. in a recent comprehensive international 
review of the content of 35 guideline development 
manuals [1]. This volume of literature is not matched by 
research into updating [2, 3] or adapting/contextualis-
ing CPGs [4–7]. Thus it would seem that de novo CPG 
development is the preferred approach, when clinicians, 
managers or policy makers are faced with clinical issues of 
local importance.
However international CPG repositories are gener-
ally freely available via the internet [8–11] and a simple 
search highlights a wealth of good quality CPGs already 
written, for a large number of clinical conditions. One 
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could query then, why clinicians, managers or policy 
makers might develop yet another local CPG, when so 
many already exist? One answer may be that if a CPG 
group decides to use guidance developed by others, there 
are usually immediate challenges related to putting it 
into practice, largely reflected by the question of whether 
the CPG can be effectively implemented in a new setting 
[12–14]. There are many issues which influence effec-
tive CPG implementation, including but not limited to 
comprehensiveness and currency of the evidence-base, 
acceptance by local policy-makers, clinicians and/or 
patients, cultural relevance, local contexts, availability of 
care, affordability, equity and access [15]. Thus it is per-
haps understandable why CPG groups in particular set-
tings choose to develop de novo CPGs, rather than use 
CPGs already written by others.
De novo CPG development (‘from scratch’) is usually 
an expensive and time-consuming business, requiring 
dedicated teams of methodologists and experts (e.g. clini-
cians, managers, policy-makers, consumers), who search, 
critique and debate the usefulness and relevance of the 
body of evidence which could provide relevant clinical 
guidance. Consequently, the financial, human resource 
and opportunity costs of de novo CPG development are 
often outside budgets of low-to-middle income countries 
(LMICs). Moreover, the disease burden in these countries 
is often higher than in middle-to-high income countries, 
and thus a focus on evidence-based disease manage-
ment is often even more urgent, to minimise wastage and 
ensure optimal care for optimal cost [16]. Thus in LMIC 
countries, building on CPGs which have been developed 
elsewhere, and using a structured process to make rec-
ommendations relevant to local contexts might not only 
be a persuasive alternative to undertaking de novo CPG 
activities, but also a way of breaking down barriers to 
implementation.
This paper proposes ways to consider the need for de 
novo CPG development when already available good 
quality CPGs might be sourced from elsewhere, and 
modified to provide guidance appropriate for local 
contexts.
Our approach
Critical elements of clinical guidance
In a paper we recently published, we proposed a CPG 
classification system [the ‘South African Guidline Evalu-
ation (SAGE) Clinical Practice Guideline Development 
Framework’] that has a base of transparent evidence syn-
thesis processes (tier one); layered with clinical contexts 
(tier two); which in turn supports end-products tailored 
specifically for different contexts, users and purposes 
(tier three)—classified as ‘evidence-based summary rec-
ommendations’, ‘patient management tools’, or ‘protocols’.
Tier 1 (evidence base)
The evidence base forms the foundation of all forms of 
clinical guidance. Without this tier, there is little to sup-
port the credibility of recommendations in terms of ‘what 
the evidence says’. Producing the evidence base is usually 
the domain of methodologists, who establish what litera-
ture is available to answer clinical questions in the CPG, 
and how believable the evidence is. The GRADE group 
produced a widely-used set of instructions to classify the 
strength of the underlying evidence for CPG recommen-
dations [very strong (benefit/risk trade-off unequivo-
cal, high quality evidence, 1A) to the very weak (benefit/
risk questionable, low quality evidence, 2C)] [17, 18]. To 
be credible, the evidence base should be derived from 
transparent, comprehensive literature reviews relevant 
to guideline questions, following the steps outlined by 
Schünemann et al. [1].
Tier 2 (expert input)
Evidence derived from experts is not always depend-
able. While expert opinion is an essential element in the 
Evidence-based Medicine model proposed by Sackett 
et al. [19], it needs to be in addition to the body of evi-
dence, not instead of it. Experts may well present a com-
prehensive understanding of the available research base, 
however they may also provide opinion that is without 
the backing of independent evidence reviews. Expert 
opinion alone runs the risk of presenting selective, non-
current or misleading (biased) views of the available evi-
dence [20–22]. However, in circumstances where there 
are evidence gaps (no research has been conducted, or 
the research is of questionable value), expert opinion is 
recognised as a credible evidence source (SIGN guide-
line developers handbook) [23]. Expert opinion garnered 
using robust qualitative research such as Delphi studies, 
provides credible ‘best available evidence’ statements in 
the absence of sound research evidence [22].
The second CPG tier we proposed requires expert 
input, as this layer is essential in determining relevance 
and applicability of research evidence to local contexts. 
Local contexts deal with a range of issues that are often 
not addressed or reported in the body of research, such 
as local systems, and operational issues such as funding 
and funding priorities, historical health service delivery, 
health priorities, health workforce type, training, mobil-
ity and availability, how decisions are made, available 
human and infrastructure resources, burden of disease, 
and patient need. In a CPG team, determining the sec-
ond layer of CPGs is usually the domain of lead clini-
cians, managers, policy-makers, funders and end-users 
(usually patients and local clinicians). However, there is 
little in the CPG literature regarding how to comprehen-
sively address the relevance and applicability of evidence, 
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to local contexts. FORM is one of the few tools that pro-
vides guidance when considering the contexts of recom-
mendations, regarding applicability to end-users and 
patients, and relevance to local healthcare environments 
[24]. This second tier usually results in ‘Context Points’ 
which enrich the Tier 1 findings, and provide information 
to assist local users to apply the research evidence.
Tier 3 (end‑user guidance documents)
This is the least well explored in the literature, and it 
refers to the way that guidance is presented to address 
end-user needs (i.e. in short form evidence summaries, 
patient management tools, decision-making algorithms, 
or protocols to do specific tasks). How recommenda-
tions are presented has a significant impact on evidence-
uptake and compliance [13, 22].
Considering the cost, time and human resource impli-
cations of de novo CPG development, we suggest that 
CPG groups should consider alternatives to de novo 
development activities. To assist CPG groups particu-
larly in LMICs to be effective and efficient, we propose 
an approach to Adopt, Contextualise or Adapt CPGs, 
using an existing high quality evidence base from inter-
national guidelines developed in other countries for the 
same target patient population and the same end-users. 
CPG groups should rather not focus on recreating Tier 
1 in the CPG development framework [25], but instead 
focus on Tier 2, where they can harness local experts with 
local knowledge to complement the existing evidence-
base, and produce Tier 3 outputs that provide locally rel-
evant and ready to implement recommendations.
To adopt, contextualise or adapt?
Adopting refers to something being accepted and put 
into use without any change [e.g. a suitcase borrowed 
and being used as it is (Fig.  1)] and with (usually) the 
intention of returning it in the same condition. Many 
diseases/health problems occur commonly around the 
world (e.g. stroke, cancer, asthma, diabetes, hyperten-
sion, back pain). There may be country-to-country vari-
ations in prevalence, however it is reasonable to expect 
that research into these conditions would be conducted, 
and published, by researchers around the world. It is also 
reasonable that comprehensive search strategies devel-
oped for Tier 1 [25] of a de novo CPG would identify all 
relevant international literature, and not just that from 
the country where the CPG is being developed. Thus, for 
a given condition, a good quality CPG developed in UK, 
for instance, could include the same literature as a good 
quality CPG developed at the same time in Australia, 
even though the two CPG development groups may 
not be aware of each other’s activities. One could argue 
therefore, that where a current, good quality CPG with 
a rigorous, defensible evidence base (Tier 1) is already 
available, it is unnecessary and inefficient to redo the 
whole development process simply to be seen to have a 
locally-developed CPG.
Following this line of thought, adopting a CPG devel-
oped elsewhere means a commitment to implement-
ing its recommendations exactly as proposed, without 
change or caveat, in a new setting. Thus all three tiers of 
a CPG developed in Australia for instance, for the man-
agement of a particular condition, may be adopted by 
another similar country with a similar healthcare sys-
tem, similar patient types, and similar economy, with the 
expectation that the recommendations will be equally 
as applicable, relevant and effective as they were in the 
parent country, in underpinning good processes and pro-
ducing desired outcomes.
Contextualising a CPG occurs when a CPG produced 
elsewhere is also adopted in its entirety, but to implement 
it effectively requires caveats and/or additional consider-
ations, to address local contexts. Contextualisation gen-
erally relates to local service delivery issues. Considering 
the suitcase analogy (Fig.  1), contextualisation occurs 
when a suitcase is borrowed, but then contextualised, 
by the addition of travel stickers, or additional locks, or 
wheels. Whilst it is still a suitcase, it is not the same as 
the original suitcase. Thus during contextualisation, the 
evidence base (Tier 1), and the resultant recommenda-
tions (Tier 3) remain the same as the original ‘borrowed’ 
guideline (i.e. they are adopted), however additional Tier 
2 processes (expert input) are essential in order for the 
recommendations in Tier 3 to be effectively implemented 
locally. The CPG contextualisation activities undertaken 
by Philippines Academy of Rehabilitation Medicine 
(PARM) are a case in point [6]. The PARM group found 
that there was no need to recreate existing guidance for 
the management of stroke, however effective implemen-
tation of international CPG recommendations in its cur-
rent setting required consideration of local contexts of 
workforce type, availability and training, patients’ physi-
cal access to care, local resources, referral systems, work-
force hierarchy and record keeping. An example of this 
occurred when the PARM group adopted the recommen-
dation for the use of the water swallow test for diagnosing 
dysphasia in acute stroke, a recommendation from the 
SIGN (2010) guidelines [26]. PARM’s contextualisation 
approach was to layer this recommendation with specific 
context points in order to ensure effective Filipino imple-
mentation [27]. The PARM context points addressed 
diagnostic tools and requisite equipment, workforce 
available and training required to administer the test, 
and specifications of when the water swallow test should 
be conducted [28]. These were mapped against mini-
mum standards of care possible (in most settings) and 
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additional standards of care (in advanced settings) ena-
bling the provision of best practice nation-wide [PARM 
STROKE GUIDELINES (http://www.eparm.org/images/
STROKE-Guideline.pdf, page 118] [28] (see Table 1).
Adapting a CPG refers to changing the CPG recom-
mendations to address local issues. This is a complex 
issue, where Tier 1 in the CPG may (or may not) be 
changed (depending on whether the guidelines questions 
remain relevant in the new setting), and adaptation may 
occur within the Tier2 process, to revise the way rec-
ommendations are worded or presented in Tier 3. Not 
adapting may mean that the CPG recommendations may 
be rendered useless in a new setting. The analogy of the 
suitcase ‘chair’ is provided (Fig. 1), where the suitcase no 
longer retains its original state, and has since been modi-
fied. An example might be found in recommendations 
for a specific drug regimen. Whilst a recommendation 
from an international, good quality CPG might be to use 
a particular drug in a high income country for a specific 
purpose, it may not be possible for this same regimen to 
be followed in a LMIC because of cost, or availability of 
the recommended drug, or contra-indications with other 
drugs commonly administered there. Another drug may 
be substituted for the recommended drug, because it is 
cheaper, more easily obtained or more locally acceptable. 
The substitute drug might also be better able to be stored 
in LMIC conditions, and may retain its potency or shelf-
life better than the initially recommended drug. There 
may be a trade-off in effectiveness or dose, in order that 
local health care providers can still deliver the best avail-
able local practices, in the face of cost, geographic, supply 
or cultural constraints.
Adopting, contextualising and adapting CPG recom-
mendations may all be relevant, at the same time, within 
Fig. 1 Suitcase analogy for adopt, adapt and contextualise
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the one CPG, depending on which recommendations 
are relevant to the users of the CPG. For instance, rec-
ommendations regarding diagnosis (i.e. signs and symp-
toms) for a condition may be readily adopted, whilst 
recommendations for management (i.e. interventions 
such as drugs or highly specialised care management) 
may require contextualisation and/or adaptation to be 
actionable locally.
Discussion
Research into CPGs has escalated over the last 
15–20 years, with a concomitant increase in theories and 
methods [1–7]. Terminology has also increased in vol-
ume and sophistication, although currently CPG terms 
can have different meanings [29]. The issue of contextu-
alisation and adaptation is a case in point. The two terms 
are used interchangeably although they have quite differ-
ent connotations (as outlined in Fig. 2), and depending on 
the approach taken, require different CPG activities. We 
contend that to contextualise is a component of adopting 
a CPG (by addressing local implementation issues with-
out changing the CPG recommendations), whereas to 
adapt a CPG requires permanent change, perhaps addi-
tional literature searches to identify local information to 
support substitution, or change of ‘parent’ CPG recom-
mendations, to ensure that CPG recommendations are 
relevant to local contexts, resources and/or culture.
Best known research into transferring CPGs from one 
setting to another is the work of the ADAPTE Collabo-
ration, which reported 24 steps in adapting CPG recom-
mendations from one setting to another process [5, 7]. 
This group defines adaptation as ‘the systematic approach 
to considering the use and/or modification of a guide-
line developed in one cultural or organizational setting 
for application in a different context. Adaptation can be 
considered as an alternative to de novo guideline develop-
ment …….
The adaptation process…….has been designed to ensure 
that the final recommendations address specific health 
questions relevant to the context of use, and address the 
needs, priorities, legislation, policies and resources in 
the target setting without undermining the validity of the 
target recommendations’ (Adaptation Resource Kit 2009 
p9) [7]. We believe that the ADAPTE group presents an 
amalgam of adaption, adoption and contextualization in 
their resource kit. The ADAPTE framework underpinned 
Table 1 Dysphagia assessment (reproduced from PARM Stroke Guidelines with permission
Context points of minimum and additional standard care of practice for dysphagia, Table 64) [28])
Used with permission from PARM
Context  
considerations
Minimum standard care of practice Additional standard care of practice
Diagnostic tools Water swallow test
Standardized clinical bedside assessment
Pulse oximetry
Videofluroscopy-modified barium swallow test (VMBS) and/or 
fiberoptic endoscopic evaluation of swallowing (FEES)
Equipment Water, food of different consistencies (pudding and buscuits-
deleted), spoon, cup, stethoscope (see Appendix 11)
Pulse oximeter
Videofluroscopy machine
Fiberoptic endoscopy machine
Workforce Physiatrist
Occupational therapist
Nurse
Radiologist
Otorlaryngologist
Speech pathologist
Resources Protocol for water swallow test (Appendices 8 and 9)
Protocol for standardized clinical bedside assessment  
(Appendix 10)
Protocol for barium swallow and FEES when it is considered to 
be pathological
Training Training needed for water swallow and standardized  
clinical bedside assessment
Specialist training in tertiary hospital
When is it done As screening tool for aspiration
Before nasogastric tube is removed or anything to be given by 
mouth
Done after a failed water swallow test, or presence of signs 
and symptoms of aspiration
Fig. 2 SAGE CPG developmnet framework
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Table 2 ADAPTE vs PARM approach
ADAPTE PARM contextualisation process
Step 1 establish an organising committee Implicit—purpose-driven
Step 2 establish a guideline topic Implicit—purpose-driven
Step 3 check whether adaptation is feasible Implicit—purpose-driven
Step 4 identify necessary resources and skills Step 1 training
Step 5 complete tasks for set up phase
Step 6 write adaptation plan Step 2 establish ‘usual’ patient journeys
Step 7 scope and purpose (determine the 
questions)
Step 3 establish scope and purpose
Step 4 establish a work plan and working groups
Step 8 search for guidelines and other 
relevant documents
Step 5 search for appropriate guidelines
Step 9 screen retrieved guidelines Step 6 screen guidelines relevant to patient journeys and identi-
fying relevant ones
Step 10 reduce a large number of retrieved 
guidelines
Step 11 assess guideline quality Step 7 critically appraise guideline quality and currency and 
retain relevant high quality guidelines
Step 8 contact developers for permission and to undertake 
external review of completed synthesised guidelines
Step 12 assess guideline currency
Step 13 assess guideline content Step 9 summarise differences between guidelines in wording of 
recommendations, ways of reporting underpinning evidence, 
and summarising strength of the evidence
Step 14 assess guideline consistency
Step 10 identify recommendations relevant to steps along the 
patient journey
Step 11 develop a process for dealing with 2 or more relevant 
recommendations
Step 12 develop PARM Writing Guide
Step 15 assess acceptability and applicability 
of recommendations
Step 13 write PARM endorsements based on strength of 
evidence
Step 16 review assessments
Step 17 select between guidelines and 
recommendations to create an adapted 
guideline
Step 14 consider applicability and generalizability of recom-
mendations to Filipino situations (NHMRC FORM) using PARM 
context points
Step 18 Prepare draft adapted guideline Step 15 map the PARM endorsements and Context Points for 
collated recommendations into the patient journey
Step 16 collate guideline chapters and edit for consistency
See Step 17 congruent with Steps 13–15 Step 17 develop an implementation 
plan congruently with Steps 13–15
Step 19 external review Step 18 present guideline at national meeting
Step 20 consult with endorsement bodies
Step 21 consult with source guideline 
developers
Step 19 undertake focused public consultation including seek-
ing suggestions for additional PARM Context Points
Step 22 acknowledge source documenta-
tion
Step 23 plan for aftercare of adapted 
guideline
Step 24 produce final guideline document
Step 20 plan and evaluate the guideline roll out
Step 21 establish partnerships
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the innovative Filipino guidelines contextualisation pro-
ject [6]. PARM recognized that it did not have the time, 
finances, and expertise or, in fact, need, to develop Fili-
pino-relevant de novo guidelines. Thus a dedicated band 
of volunteers embarked on the process of using others’ 
work to inform their practices. This group recognized 
and addressed the lack of detail in the ADAPTE process 
on ‘how to’ transfer recommendations from guidelines 
developed in high income country settings to a LMIC 
setting, where healthcare policy and contexts, funding, 
workforce, resources and training were significantly dif-
ferent from those in the parent CPGs. This particularly 
reflected gaps between Steps 14 and 17 in the ADAPTE 
resource manual, relating to just how to take recom-
mendations from one setting and put them into place 
in another (Table 2). The PARM group debated and dif-
ferentiated between the notions of ‘adaptation’ and ‘con-
textualisation’, particularly regarding whether changes 
were to be made to the parent CPG. The PARM group 
proposed an innovative contextualisation approach of 
mapping multiple relevant best-practice guideline rec-
ommendations into a typical Filipino patient pathway, 
and then developing local ‘context points’ relevant to 
Filipino healthcare settings to support seamless uptake 
and implementation of best evidence [6]. This work has 
since been recognized as best practice for LMIC by the 
International Society of Physical and Rehabilitation Med-
icine (ISPRM), as a practical cost-effective and efficient 
alternative approach to developing local context de novo 
CPGs [30].
The differences between the ADAPTE framework and 
the PARM group’s processes are outlined in Table 2.
Conclusion
CPGs are integral to the delivery of best practice care. 
The work required to develop and update the evidence 
base underpinning CPGs needs to be ongoing, to ensure 
currency of the evidence base underpinning recommen-
dations. However the utility, applicability and relevance 
of recommendations to local settings requires significant 
investment from local experts and opinion leaders [25]. 
Clear decisions about using existing evidence sources, 
and adopting (with or without contextualising) or adapt-
ing, offers persuasive ways forward for CPG groups, to 
ensure that scarce resources are focused on implementa-
tion. CPG terminology will continue to evolve, and gain 
greater clarity, as more groups become engaged with the 
processes underlying putting the best evidence into prac-
tice in ways which address local need.
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